Total Funding
1
39
Total FundingVenture - Series Unknown raised
Growth Score 1 in past quarter
0 pts
Heat Score 39 in past quarter
3 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
103620
SmartPharm Therapeutics is a second-generation gene-encoded therapeutics company.
Acquired by 
Sorrento Therapeutics
Leon Hebert Jr: General CounselPast Role: Partners Innovation Fund, Senior Business Strategy & Licensing Manager- Robert Allen: Chief Scientific Officer
About the Company
SmartPharm Therapeutics is a second-generation gene-encoded therapeutics company that has benefited from the first decades of learning in gene therapy development to produce an evolved therapeutic platform. They integrate these insights with key technologies and engineering capabilities to enable them to produce optimal gene-encoded therapeutics
for patients.
SmartPharm is focused on “gene-encoded therapeutics”. It is a subset of gene therapy that seeks to insert nucleic acids (mRNA or DNA) into cells to make normal versions of a missing or abnormal program or to produce an entirely new type of protein that has therapeutic benefit.